472 related articles for article (PubMed ID: 31371221)
21. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
22. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
23. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
24. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
[TBL] [Abstract][Full Text] [Related]
25. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
26. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
27. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
28. IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.
Rotbain EC; Frederiksen H; Hjalgrim H; Rostgaard K; Egholm GJ; Zahedi B; Poulsen CB; Enggard L; da Cunha-Bang C; Niemann CU
Haematologica; 2020 Jun; 105(6):1621-1629. PubMed ID: 31582540
[TBL] [Abstract][Full Text] [Related]
29. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Fischer K; Bahlo J; Fink AM; Goede V; Herling CD; Cramer P; Langerbeins P; von Tresckow J; Engelke A; Maurer C; Kovacs G; Herling M; Tausch E; Kreuzer KA; Eichhorst B; Böttcher S; Seymour JF; Ghia P; Marlton P; Kneba M; Wendtner CM; Döhner H; Stilgenbauer S; Hallek M
Blood; 2016 Jan; 127(2):208-15. PubMed ID: 26486789
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Shanafelt TD; Wang XV; Kay NE; Hanson CA; O'Brien S; Barrientos J; Jelinek DF; Braggio E; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Little RF; Erba H; Stone RM; Litzow M; Tallman M
N Engl J Med; 2019 Aug; 381(5):432-443. PubMed ID: 31365801
[TBL] [Abstract][Full Text] [Related]
31. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
32. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
33. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
[TBL] [Abstract][Full Text] [Related]
35. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
[TBL] [Abstract][Full Text] [Related]
37. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
38. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H
Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428
[TBL] [Abstract][Full Text] [Related]
39. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.
Visentin A; Bonaldi L; Rigolin GM; Mauro FR; Martines A; Frezzato F; Imbergamo S; Scomazzon E; Pravato S; Bardi MA; Cavallari M; Volta E; Cavazzini F; Nanni M; Del Giudice I; Facco M; Guarini A; Semenzato G; Foà R; Cuneo A; Trentin L
Br J Cancer; 2019 Jul; 121(2):150-156. PubMed ID: 31209327
[TBL] [Abstract][Full Text] [Related]
40. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
